Der Markt für Krebs-Biomarker wurde im Jahr 2022 auf 18.436,36 Millionen US-Dollar geschätzt und dürfte die USA erreichen Es wird geschätzt, dass es bis 2028 34.857,12 Millionen US-Dollar beträgt und zwischen 2022 und 2028 voraussichtlich um 11,1 % wachsen wird
Biomarker, ein biologisches Molekül, wird in Blut, Gewebe oder anderen Körperflüssigkeiten gefunden und ist ein Zeichen für einen normalen oder abnormalen Prozess. Ein Biomarker wird verwendet, um zu sehen, wie gut der Körper auf die Behandlung einer Krankheit oder eines Leidens reagiert.
Market Insights
Neue Produkteinführungen und FDA-Zulassungen sowie technologischer Fortschritt treiben das Marktwachstum voran
Marktteilnehmer stellen eine breite Palette von Krebs-Biomarkern her, die maximale Vorteile und eine frühzeitige Diagnose bieten. Im April 2021 startete Amgen den Biomarker Assist, ein Programm, das mehr Patienten mit metastasiertem (Stadium IV) nicht-kleinzelligem Lungenkrebs (NSCLC) den Zugang zu Biomarker-Tests ermöglichen soll. Das Testen von Biomarkern zum Zeitpunkt der Diagnose ist ein entscheidender erster Schritt, um den Patienten die richtige Behandlung zu verschaffen. Durch Biomarker Assist können berechtigte Patienten bei Biomarker-Tests sparen.
Darüber hinaus Im März 2022 hat Vela Diagnostics neue fokussierte (60 Gene) und umfassende (525 Gene) Next-Generation-Sequencing (NGS)-basierte Panels zum Nachweis von RNA- und DNA-Krebsbiomarkern aus formalinfixierten, in Paraffin eingebetteten (FFPE) Gewebeproben auf den Markt gebracht. Zu den neuen Pan-Cancer-Gen-Panels gehören das fokussierte OncoKey SL 60 Plus Panel und das umfassende OncoKey SL 525 Plus Panel.
Darüber hinaus brachte BioGenex im Dezember 2021 drei neue primäre immunhistochemische (IHC) Antikörper auf den Markt, darunter CD8A, CD163 und CD56, für die Krebsdiagnose.
Darüber hinaus haben jüngste Fortschritte bei Krebsimmuntherapien zu lang anhaltenden klinischen Reaktionen bei Patienten geführt. Krebsimmuntherapien ersetzen zunehmend traditionelle Behandlungsstandards und erweitern die Therapielandschaft für Krebspatienten. Forscher konzentrieren sich darauf, Moleküle im Blut zu finden, die das Auftreten von Krebserkrankungen signalisieren können. Zur Diagnose von Eierstock- und Prostatakrebs werden neben anderen Tests das Krebsantigen (CA)125 und das prostataspezifische Antigen (PSA) verwendet.
Darüber hinaus beschleunigten Fortschritte bei Hochdurchsatz-Omics-Technologien, einschließlich Genomik, Proteomik, Transkriptomik und Metabolomik, das Tempo der Biomarker-Entdeckung. Kürzlich wurde das Konzept der Identifizierung zirkulierender Tumor-DNA durch eine Flüssigkeitsbiopsie entwickelt ist in die klinische Realität übergegangen. Die Society for Immunotherapy of Cancer (SITC) hat erneut eine Biomarker-Immun-Task Force einberufen, um die neuesten Technologien zu überprüfen, aktuelle Hürden zu identifizieren und Empfehlungen für den Bereich abzugeben. Daher hat der jüngste technologische Fortschritt viele potenzielle Biomarker ermöglicht und die Entwicklung neuer Biomarker erneuert und das Wachstum von Markt für Krebs-Biomarker
< strong>Strategische Einblicke
Markteinblicke - Chancen
Schwellenländer in Entwicklungsländern Bereitstellung lukrativer Marktchancen im Prognosezeitraum
Emerging Märkte wie der asiatisch-pazifische Raum bieten bedeutenden Marktteilnehmern zahlreiche Möglichkeiten, ihr Geschäft auszubauen. Aufgrund der großen Zahl von Krebspatienten und des wachsenden Medizintourismus in Entwicklungsländern konzentrieren sich die meisten großen Akteure auf Schwellenländer wie Indien, China und andere. Die meisten Schwellenländer sind bevorzugte Orte für Medizintourismus.
Gemäß Nach Angaben des Australian Institute of Health and Welfare werden im Jahr 2021 151.000 neue Krebsfälle diagnostiziert. Darüber hinaus besuchten laut dem Malaysia Healthcare Travel Council im Jahr 2020 mehr als 2 Millionen Menschen Malaysia zu Gesundheitszwecken, was die Einnahmen aus dem Medizintourismus auf etwa 680 Millionen verdoppelte. Die niedrigen Kosten für Operationen und fortschrittliche Technologien mit kürzeren Wartezeiten für Eingriffe in der Region dürften die Nachfrage nach Krebs-Biomarkern steigern.
Daher wird erwartet, dass der wachsende Medizintourismus in Schwellenländern und die zunehmende Krebsprävalenz im asiatisch-pazifischen Raum im Prognosezeitraum erhebliche Wachstumschancen für die auf dem Markt für Krebsbiomarker tätigen Akteure bieten werden.< /span>
Biomarker Type-Based Insights
Der Markt für Krebsbiomarker ist basierend auf dem Biomarkertyp in genetische Biomarker und Protein unterteilt Biomarker und andere. Das Protein-Biomarker-Segment hatte im Jahr 2022 den größten Marktanteil und wird im Prognosezeitraum voraussichtlich die höchste Wachstumsrate verzeichnen.
Markt für Krebs-Biomarker, nach Biomarker-Typ – 2022 und 2028
Profiling Technology-Based Insights
Profiling Technology-Based Insights
Der Markt für Krebsbiomarker ist nach Profilierungstechnologie in Omics-Technologien, Bildgebungstechnologien, Immunoassays, Zytogenetik, und Bioinformatik. Das Segment Omics-Technologien hatte im Jahr 2022 den größten Marktanteil und wird voraussichtlich im Zeitraum 2022–2028 die höchste Wachstumsrate verzeichnen.
Cancer Type-Based Insights
Der Markt für Krebsbiomarker ist je nach Krebsart in Brustkrebs, Lungenkrebs, Prostatakrebs, Leukämie, Blasenkrebs und andere unterteilt. Im Jahr 2022 hielt das andere Segment den größten Marktanteil. Es wird jedoch erwartet, dass das Segment Lungenkrebs in den kommenden Jahren die schnellste Wachstumsrate verzeichnen wird.
Anwendungsbasierte Einblicke
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
National Cancer Institute defined biomarker as a biological molecule found in blood, or tissues or other body fluids that is a sign of a standard or abnormal process. A biomarker is employed to ascertain however well the body responds to a treatment for a malady or condition. Cancer biomarkers area unit the molecules that aid within the examination similarly because the treatment of various kinds of cancer. These molecules are often evaluated by aggregation samples like stool, neoplasm tissue, blood, urine, or alternative tissues or bodily fluids.
The key factors that are driving growth of the market are growing cancer prevalence across the globe, new product launches and FDA approvals, and technological advancements.
Unfavorable regulatory and reimbursement scenario is the major factor hindering the market growth.
Based on biomarker types, the protein biomarker segment held largest share of the market and protein biomarker segment is projected to register the highest CAGR during the forecast period.
The cancer biomarkers report contains forecast of 2019 to 2027.
The List of Companies
- Bio-Rad Laboratories, Inc.
- Thermo Fisher Scientific, Inc.
- F. Hoffmann-La Roche Ltd.
- QIAGEN N.V.
- Illumina, Inc.
- Myriad Genetics, Inc.
- Hologic Inc.
- Quest Diagnostics Incorporated
- bioMérieux SA
- Creative Diagnostics
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Apr 2024
Bioprocessing Market
Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product (Instruments, and Consumables and Accessories), Scale of Operation (Commercial Operations and Clinical Operations), Process (Downstream Bioprocess and Upstream Bioprocess), Application (Monoclonal Antibodies, Vaccines, Recombinant Protein, Cell and Gene Therapy, and Others), End User (Biopharmaceutical Companies, Contract Manufacturing Organization, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Apr 2024
Bioproduction Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product (Biologics and Biosimilars, Vaccines, Cell and Gene Therapies, Nucleic Acid Therapeutics, and Others), Application (Rheumatoid Arthritis, Hematological Disorders, Cancer, Diabetes, Cardiovascular Diseases, and Others), Equipment (Upstream Equipment, Downstream Equipment, Bioreactors, and Consumables and Accessories), End User (Biopharmaceutical Companies, Contract Manufacturing Organizations, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Apr 2024
ELISA Diagnostic Test Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Adoption (Human and Veterinary), Test Type (Sandwich ELISA, Indirect ELISA, Competitive ELISA, and Multiple & Portable ELISA), Application (Autoimmune Diseases, Infectious Diseases, Cancer Diagnosis, Protein Quantification, and Others), End User (Hospitals & Diagnostic Centers, Pharmaceutical & Biotechnology Companies, Veterinary Hospitals & Diagnostic Laboratories, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Apr 2024
Swine Diagnostics Market
Size and Forecasts (2022 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Product Type [Immunoassays Kits, PCR Kits, Hemagglutination Inhibition (HI), and Others], Sample Type (Blood, Oral Fluids, Nasal Swabs, Tissue Samples, and Others), Disease [African Swine Fever (ASF)/Classical Swine Fever (CSF), Respiratory Diseases, Porcine Circovirus, Porcine Epidemic Diarrhea, Swine Dysentery, and Others], End User (Veterinary Hospitals, Veterinary Clinics, and Other End Users), and Geography
Apr 2024
Microbial Identification Methods Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Method (Genotypic, Phenotypic, and Proteotypic), Type (Bacterial Identification System, Microbial Enumeration System, Bacterial Resistance Identification Systems, Microbiology Analyzer, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and Latin America)
Apr 2024
Biopharmaceuticals Market
Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (Monoclonal Antibodies, Recombinant Vaccines, Conventional Vaccines, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Recombinant Enzymes, Cell & Gene Therapies, Cytokines/Interferon/Interleukins, and Others) and Application (Oncology, Inflammatory & Infectious Disease, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders & Growth Failure, Cardiovascular Diseases, Neurological Diseases, and Others)
Apr 2024
GMP Cell Therapy Consumables Market
Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Kits, Reagents/Molecular Biology Reagents, Growth Factors/Cytokines and Interleukins, and Others), Cell Therapy (NK Cell Therapy, Stem Cell Therapy, T-Cell Therapy, and Others), Process (Cell Collection and Characterization/Sorting and Separation, Cell Culture and Expansion/Preparation, Cryopreservation, Cell Processing and Formulation, Cell Isolation and Activation, Cell Distribution/Handling, Process Monitoring and Control/Readministration/Quality Assurance, and Others), and End Use (Clinical, Commercial, and Research)